362 related articles for article (PubMed ID: 32835827)
1. TGFβ-Directed Therapeutics: 2020.
Teicher BA
Pharmacol Ther; 2021 Jan; 217():107666. PubMed ID: 32835827
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
4. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
5. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
[TBL] [Abstract][Full Text] [Related]
6. Activated Endothelial TGFβ1 Signaling Promotes Venous Thrombus Nonresolution in Mice Via Endothelin-1: Potential Role for Chronic Thromboembolic Pulmonary Hypertension.
Bochenek ML; Leidinger C; Rosinus NS; Gogiraju R; Guth S; Hobohm L; Jurk K; Mayer E; Münzel T; Lankeit M; Bosmann M; Konstantinides S; Schäfer K
Circ Res; 2020 Jan; 126(2):162-181. PubMed ID: 31747868
[TBL] [Abstract][Full Text] [Related]
7. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma.
Strait AA; Woolaver RA; Hall SC; Young CD; Karam SD; Jimeno A; Lan Y; Raben D; Wang JH; Wang XJ
Commun Biol; 2021 Aug; 4(1):1005. PubMed ID: 34433873
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Yoo C; Oh DY; Choi HJ; Kudo M; Ueno M; Kondo S; Chen LT; Osada M; Helwig C; Dussault I; Ikeda M
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461347
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
10. Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.
Cho JH; Oh AY; Park S; Kang SM; Yoon MH; Woo TG; Hong SD; Hwang J; Ha NC; Lee HY; Park BJ
Mol Cancer Ther; 2018 Nov; 17(11):2271-2284. PubMed ID: 30135214
[TBL] [Abstract][Full Text] [Related]
11. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
12. A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment.
Huynh LK; Hipolito CJ; Ten Dijke P
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31744193
[TBL] [Abstract][Full Text] [Related]
13. Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies.
Strait AA; Wang XJ
Mol Carcinog; 2022 Feb; 61(2):239-242. PubMed ID: 34793609
[TBL] [Abstract][Full Text] [Related]
14. Targeting transforming growth factor-β signaling for enhanced cancer chemotherapy.
Chen J; Ding ZY; Li S; Liu S; Xiao C; Li Z; Zhang BX; Chen XP; Yang X
Theranostics; 2021; 11(3):1345-1363. PubMed ID: 33391538
[TBL] [Abstract][Full Text] [Related]
15. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA
Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062
[TBL] [Abstract][Full Text] [Related]
16. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.
Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A
Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide induces TIMP-1 expression by activating the transforming growth factor beta-Smad signaling pathway.
Akool el-S; Doller A; Müller R; Gutwein P; Xin C; Huwiler A; Pfeilschifter J; Eberhardt W
J Biol Chem; 2005 Nov; 280(47):39403-16. PubMed ID: 16183640
[TBL] [Abstract][Full Text] [Related]
19. TGFβ Signaling in the Tumor Microenvironment.
Goulet CR; Pouliot F
Adv Exp Med Biol; 2021; 1270():89-105. PubMed ID: 33123995
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of transforming growth factor beta type I receptor contributes to the malignancy of human colon carcinoma cells.
Wang J; Han W; Zborowska E; Liang J; Wang X; Willson JK; Sun L; Brattain MG
J Biol Chem; 1996 Jul; 271(29):17366-71. PubMed ID: 8663343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
